Litcius/Paper detail

De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study

Sabine R. de Wild, Linda de Munck, Janine M. Simons, Janneke Verloop, Thijs van Dalen, Paula H.M. Elkhuizen, Ruud Houben, A. Elise van Leeuwen, Sabine C. Linn, Ruud M. Pijnappel, Philip Poortmans, Luc J. A. Strobbe, Jelle Wesseling, Adri C. Voogd, Liesbeth Boersma

2022The Lancet Oncology78 citationsDOIOpen Access PDF

Topics & Concepts

MedicineRadiation therapyBreast cancerClinical endpointGuidelineAxillaProspective cohort studyChemotherapyOncologyCancerInternal medicineRandomized controlled trialPathologyBreast Cancer Treatment StudiesBreast Lesions and CarcinomasMedical Imaging Techniques and Applications
De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study | Litcius